<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663386</url>
  </required_header>
  <id_info>
    <org_study_id>3103018</org_study_id>
    <nct_id>NCT04663386</nct_id>
  </id_info>
  <brief_title>Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway</brief_title>
  <acronym>BufoSwitch</acronym>
  <official_title>Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway; A Retrospective, Observational Study to Evaluate the Impact on Disease Control in Patients With Asthma and/or Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, multicentre, non-interventional, observational study in patients&#xD;
      with asthma and/or COPD who are treated with budesonide-formoterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder&#xD;
      inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch&#xD;
      patients to the inhaler with the lowest price. The pharmacist will train the patient on how&#xD;
      to use the new inhaler. All patients whose eligible inhaler switch occurred between 1st July&#xD;
      2018 and 1st March 2019 will be eligible for the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Target recruitment not reached&#xD;
  </why_stopped>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Actual">September 14, 2021</completion_date>
  <primary_completion_date type="Actual">September 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control</measure>
    <time_frame>24 months</time_frame>
    <description>The number of asthma and/or COPD exacerbations during the 12 months pre-switch and the 12 months post-switch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Budesonide-formoterol dose</measure>
    <time_frame>24 months</time_frame>
    <description>The change in the treatment dose of budesonide-formoterol at the time of the eligible switch and at the end of the post-switch period (e.g. 12 months post-switch).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Training at pharmacy</measure>
    <time_frame>24 months</time_frame>
    <description>The correlation between inhaler training given at pharmacy and exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilisation</measure>
    <time_frame>24 months</time_frame>
    <description>The number of asthma and/or COPD related hospitalisations, emergency room visits and visits to physicians 12 months pre-switch and 12 months post-switch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhaler switch</measure>
    <time_frame>24 months</time_frame>
    <description>The number of re-switches after the first 'eligible' switch and the reasons for that switch.</description>
  </secondary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide-Formoterol</intervention_name>
    <description>Dry powder inhaler</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with asthma and/or COPD treated with budesonide-formoterol DPI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent has been obtained.&#xD;
&#xD;
          2. Male or female patients with a diagnosis of asthma and/or COPD whose&#xD;
             budesonide-formoterol DPI was switched to another budesonide-formoterol DPI at&#xD;
             pharmacy between 1st July 2018 and 1st March 2019 (referred to as the eligible&#xD;
             switch).&#xD;
&#xD;
          3. Age ≥12 years at time of switch.&#xD;
&#xD;
          4. Treated with budesonide-formoterol for at least 12 months before the eligible switch&#xD;
             (pre-switch period) and 12 months after the eligible switch (post-switch period).&#xD;
             Re-switch(es) of inhaler are allowed during the post-switch period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patient has declined participation in the study or failed to respond to the invitation&#xD;
        to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorn Ossum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flattum Legesenter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flattum Legesenter</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

